Skip to main content

For educational and research purposes only. Not medical advice. Consult a healthcare professional.

Home Browse Peptides Research Calculator Stack Builder Protocol Builder

Core

Calculator Stack Builder Protocol Builder

More

Best For (Goal Discovery)Compare Tool Guides Interaction Checker Accumulation Plotter Cost Calculator Blend Calculator

OpenPep

Making peptide research accessible. Science-backed data, plain-English summaries, evidence you can trust.

info@openpep.com

Explore

Browse by Goal
All Peptides
Reconstitution Calculator
Stack Builder

Community

Forum — Coming Soon
Protocol Sharing
Stack Library

Legal

Terms of Service
Privacy Policy
Disclaimer

Stay in the loop

Weekly peptide research & purity updates. No spam.

Email address

All information provided on this site is for educational and research purposes only. This content is not medical advice. Always consult with a qualified healthcare professional before making any decisions related to your health.

© 2026 OpenPep. All rights reserved.

Home Peptides Research Tools Pep+

Research Disclaimer

All information on this website is intended strictly for educational and research purposes only.

The content on OpenPep — including peptide profiles, clinical trial summaries, dosing information, and reconstitution calculators — must not be used for:

Human or animal consumption guidance
Diagnosing, treating, curing, or preventing any disease
Self-medication or self-treatment decisions

OpenPep aggregates publicly available clinical trial data and research. We do not sell, distribute, or recommend any substances. All AI-generated summaries are interpretations of published research and may contain errors.

I am at least 18 years of ageI understand that all content on this site is for educational and research purposes onlyI will not use information from this site as a substitute for professional medical advice, diagnosis, or treatmentI accept full responsibility for how I use information found on this site

I agree to the Terms of Service and Privacy Policy(Terms, Privacy)

All Peptides

Semaglutide | OpenPep

Semaglutide

FDA Approved

Semaglutide (GLP-1 receptor agonist)

Strong

156 trials indexed

Weight Loss / Fat Loss Hormone Optimization

For educational and research purposes only. Not medical advice.

AI Summary

Semaglutide is the most extensively studied GLP-1 RA with 150+ trials. The STEP program demonstrated 15-17% weight loss, and SELECT trial proved 20% cardiovascular risk reduction. Available as Ozempic (diabetes), Wegovy (obesity), and Rybelsus (oral).

Practical Usage

Best Time

Any time, same day each week

Method

subcutaneous

Frequency

Once weekly

Half-life

~7 days

Cycle Length

Ongoing (per prescription)

Storage

Refrigerate pen at 2-8°C before first use.

Published Dosing Ranges

Beginner

Intermediate

Experienced

Only available to OpenPep members

Create an account to access peptide research data.

Create Account Sign in

Contraindications

•
•
•

Only available to OpenPep members

Create an account to access peptide research data.

Create Account Sign in

Stacking & Compatibility

TirzepatideConflict

Do NOT combine GLP-1 agonists. Overlapping receptor activation increases risk of severe GI side effects (nausea, vomiting, pancreatitis) with no additional benefit.

SurvodutideConflict

Survodutide is a GLP-1/glucagon dual agonist. Combining with semaglutide (pure GLP-1 agonist) doubles GLP-1 receptor activation. High risk of severe nausea, vomiting, and pancreatitis.

RetatrutideConflict

Both activate GLP-1 receptors. Retatrutide already provides GLP-1 + GIP + glucagon agonism. Adding semaglutide causes GLP-1 receptor overstimulation with dangerous GI and pancreatic risks.

Clinical Trials & Studies1545 indexed

📊Meta-analysis

Efficacy of GLP-1 Receptor Agonist-Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta-Analysis of Randomized Controlled Trials.

Journal of diabetes 17 (4) :e70082 · 2025-04-01

Strong

👤Human

Advancing precision health discovery in a genetically diverse health system.

Cell 189 (9) :2533-2555.e31 · 2026-04-30

Strong

📊Meta-analysis

GLP-1 Receptor/Dual Agonists for Weight Loss: A Systematic Review and Network Meta-Analysis of RCTs.

Diabetes, obesity & metabolism 28 (6) :5043-5057 · 2026-06-01

Strong

📊Meta-analysis

Effects of subcutaneous or oral semaglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.

Frontiers in cardiovascular medicine 12 :1731127 · 2025-01-01

Strong

🧬Pre-clinical

Weight Loss With GLP-1 Agonists in Nondiabetic Adults: Systematic Review and Network Meta-Analysis.

Obesity (Silver Spring, Md.) · 2026-04-05

Strong

Science

Mechanism of Action

Selective GLP-1 receptor agonist that mimics the incretin hormone GLP-1. Reduces appetite, slows gastric emptying, enhances insulin secretion, and has cardioprotective effects.

Novo Nordisk

Community-Reported Research Interests

Reported by the community. These may not be supported by clinical evidence and are not medical recommendations.

Weight lossBlood sugar managementCardiovascular protectionAppetite control